 Humanigen Inc NASDAQ: HGEN has submitted an application to the FDA seeking Emergency Use Authorization EUA for lenzilumab to treat patients hospitalized with COVID-19. The application is based on positive results from the LIVE-AIR Phase 3 clinical trial evaluating the ability of lenzilumab to improve the likelihood of survival without ventilation SWOV in newly hospitalized COVID-19 patients. 